Introduction
Aspergillus species are among the most ubiquitous of the airborne saprophytic fungi. Over the past two decades, the incidence of invasive aspergillosis has risen inexorably. 1 Invasive aspergillosis is now the most common invasive mould infection worldwide. 2 Itraconazole and amphotericin B are the only two agents licensed for the initial treatment of Aspergillus infections. Therapeutic failure in invasive aspergillosis is frequent with both agents. Resistance to amphotericin B has been reported in Aspergillus fumigatus, 3 Aspergillus flavus 4 and Aspergillus terreus, 5 and to itraconazole in A. fumigatus. 6, 7 Thus new agents are being studied in invasive aspergillosis. Some compounds are related to the existing compounds, such as posaconazole. Resistance within classes may become problematic. 7a A different approach to the treatment of refractory infections is the use of combinations of drugs already in use, even if one of them lacks activity against Aspergillus. A good result would be synergy or an additive effect of both drugs in combination.
In this work we studied the in vitro interaction of the allylamine terbinafine with itraconazole, fluconazole, amphotericin B and flucytosine against four species of Aspergillus. Thus we have extended the existing data on interactions already studied 8, 9 by including new drugs and Aspergillus species combinations, as well as cidality tests. Terbinafine is a synthetic naphthalenemethanamine that inhibits squalene epoxidase, a key enzyme in ergosterol biosynthesis of fungi. Its mode of action is highly selective, i.e. it is much more inhibitory to fungal than to mammalian sterol biosynthesis. Terbinafine can be administered orally and extensive use in humans indicates that it is well tolerated. It is highly potent against dermatophytes in vitro 10 and is also active in vitro against Aspergillus spp. 11,12 It has also been reported to be as effective as amphotericin B and itraconazole in the treatment 
Antifungal susceptibility testing
Drug interactions were assessed using a chequerboard titration broth microdilution-based method, derived from published work from our laboratory, validated in vivo and capable of detecting itraconazole resistance in A. fumigatus but that failed to do so for amphotericin B. 14, 15 Testing of all drugs was performed in a single batch of casitone (pH 7.0; Difco, Detroit, MI, USA) supplemented with 2% glucose, or, for itraconazole only, also in RPMI-1640 medium (with L-glutamine, without bicarbonate) (Sigma) supplemented with 2% glucose, buffered to pH 7.0 with 0.165 M MOPS. Previous work has shown casitone and RPMI-1640 to be essentially equivalent for itraconazole, terbinafine and amphotericin B, with slightly lower MICs in casitone. Doubling dilutions of each drug, at a concentration four times the targeted final concentration, were prepared in 50 µL volumes of the medium in the wells of a flat-bottomed microtitre plate. Then 50 µL of the other drug tested, at a concentration of four times the targeted final concentration, was dispensed. Final drug concentration ranges employed were chosen according to the MIC previously obtained for each strain, in order to be able to 8 When only antagonism appeared, the higher FIC values were taken. The lower one was taken in the rest of cases. FIC reproducibility was studied for the drugs that gave synergy in combination with terbinafine (itraconazole and fluconazole).
To determine the minimal fungicidal concentrations (MFCs), 100 µL samples were withdrawn from the wells containing each drug alone and in combination and for wells containing all concentrations above the MIC. The samples were inoculated on to Sabouraud dextrose agar plates, and the liquid was allowed to dry. The plates were then streaked with a sterile loop and incubated at 37°C for 48 h. The MFC was defined as the lowest concentration of the drug alone and in combination at which no colonies grew (>99.99% kill). Fractional fungicidal concentrations (FFCs) were computed as FICs, with the same interpretation for interactions of fungicidality.
Results

Itraconazole
Itraconazole was synergic in its interaction with terbinafine (MICs) with two A. fumigatus, both A. niger and both A. terreus isolates, in both testing media (Tables 1 and 2 ). Remarkable synergy (FIC = 0.281) was seen with the itraconazoleresistant isolate AF72. For these isolates synergy was also demonstrated in MFCs, except for the three A. fumigatus isolates, for which an additive effect was seen with casitone and indifference for two of them in RPMI. Itraconazole MICs for susceptible isolates fell from 0.125-0.5 mg/L in RPMI to 0.007-0.125 mg/L in combination with terbinafine. The 
Discussion
Overall, our data indicate that the combination of subinhibitory concentrations of terbinafine with itraconazole or fluconazole enhances the in vitro activity of both triazoles against A. fumigatus, A. niger, A. terreus and A. flavus, although to a different extent depending on the species. This effect includes an important reduction in MFC. We incorporated in our study an in vivo itraconazole-resistant A. fumigatus strain (AF72) that is probably resistant by virtue of enhanced efflux of itraconazole from the cell. 7 The synergic effect of the combination terbinafine-itraconazole was even more impressive for that isolate than for the other A. fumigatus ones. Table 1 . In published work from our laboratory 11 we reported that terbinafine has potent in vitro activity against A. flavus 16 No intravenous preparation is available. Thus the pharmacodynamics in patients are favourable for non-fumigatus infections but not for those caused by A. fumigatus. However, in combination with an azole, terbinafine MICs fall 4-fold for A. fumigatus, providing a more favourable pharmacodynamic relationship for response. Nevertheless, the in vivo correlation for these in vitro interactions is difficult to establish due to the difficulties of ensuring bioavailability of terbinafine in animal models.
We believe that these observations of synergy may be significant for several reasons: (i) the in vitro method employed derives from an in vivo validated one, capable of detecting itraconazole resistance in A. fumigatus; (ii) we have used a stringent criterion for the definition of synergy; (iii) FIC reproducibility is good when synergy is observed; and (iv) both terbinafine and itraconazole ultimately block ergosterol synthesis-terbinafine earlier in the pathway (squalene to squalene epoxide) than itraconazole (lanosterol to ergosterol). There are several examples of a proven synergic interaction between two antibacterial compounds acting at different steps of the same pathway. Possibly the best known example is the case of the combination of trimethoprim and the sulphonamides inhibiting folate metabolism.
With respect to amphotericin B and flucytosine, combination with terbinafine resulted in an indifferent or, often, even antagonistic effect on MICs and MFCs. A clinical trial of combined terbinafine (750 mg daily) and amphotericin B has been concluded and unpublished results indicate a worse outcome in the terbinafine combination arm compared with amphotericin B alone. Based on our in vitro results, a worse outcome in the combination group would have been anticipated.
The in vitro interaction of terbinafine with amphotericin B, fluconazole, itraconazole and voriconazole has already been studied against a number of difficult-to-treat fungal pathogens in vitro, showing potent synergy with these azoles, and in some cases with amphotericin B. 8, 17 Regarding Aspergillus, the activity of terbinafine in combination with itraconazole, fluconazole, voriconazole or amphotericin B has been shown to be synergic, or sometimes additive, against several A. fumigatus isolates and one of A. niger. 8 Another study showed synergic activity of terbinafine with itraconazole against A. flavus, A. niger, A. terreus, Aspergillus glaucus, Aspergillus clavatus, Aspergillus candidus and particularly against A. fumigatus. 9 Our results with amphotericin B differ from those obtained in these previous studies. Since no in vitro method has been validated to be capable of detecting in vivo amphotericin B resistance, 15 any in vitro susceptibility testing result involving this drug should be interpreted with caution.
In conclusion, these findings suggest that addition of terbinafine to triazole regimens may be useful in the treatment of infections caused by Aspergillus. In contrast, the combination of amphotericin B and terbinafine should be avoided. Clinical studies are warranted to further elucidate the potential utility of this combination therapy. 
